Envoy Medical Receives Nasdaq Extension for Bid Price Compliance, Considers Reverse Split

summarizeSummary

Envoy Medical received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule, avoiding immediate delisting but indicating a potential reverse stock split.

check_boxKey Events

• Failed Bid Price Compliance

  Envoy Medical did not meet the Nasdaq $1.00 minimum bid price requirement by the May 18, 2026 deadline, following an initial notice on November 19, 2025.

• Granted 180-Day Extension

  Nasdaq provided an additional 180-day period, until November 16, 2026, for the company to regain compliance, based on meeting other listing requirements.

• Potential Reverse Stock Split

  The company informed Nasdaq of its intention to cure the deficiency, including by effecting a reverse stock split if necessary.

auto_awesomeAnalysis

Envoy Medical failed to meet Nasdaq's $1.00 minimum bid price requirement by the May 18, 2026 deadline. While this avoids immediate delisting, the company received a 180-day extension until November 16, 2026, and stated its intent to cure the deficiency, potentially through a reverse stock split. This signals continued struggles with its stock price and introduces the risk of a reverse split, which often carries negative investor sentiment.